Last update 18 Oct 2025

Bemarituzumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti-fgfr2 monoclonal antibody fpa144, Anti-FGFR2b antibody, 贝马利珠单抗
+ [2]
Target
Action
antagonists
Mechanism
FGFR2 antagonists(Fibroblast growth factor receptor 2 antagonists)
Originator Organization
Inactive Organization
Drug Highest PhasePhase 3
First Approval Date-
RegulationOrphan Drug (United States), Orphan Drug (European Union), Breakthrough Therapy (China), Special Review Project (China), Orphan Drug (Australia)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
FGFR2b positive gastroesophageal junction cancerPhase 3
China
05 Jun 2023
FGFR2b positive gastroesophageal junction cancerPhase 3
China
05 Jun 2023
Gastrooesophageal junction cancerPhase 3
United States
14 Mar 2022
Gastrooesophageal junction cancerPhase 3
China
14 Mar 2022
Gastrooesophageal junction cancerPhase 3
Japan
14 Mar 2022
Gastrooesophageal junction cancerPhase 3
Argentina
14 Mar 2022
Gastrooesophageal junction cancerPhase 3
Australia
14 Mar 2022
Gastrooesophageal junction cancerPhase 3
Austria
14 Mar 2022
Gastrooesophageal junction cancerPhase 3
Belgium
14 Mar 2022
Gastrooesophageal junction cancerPhase 3
Brazil
14 Mar 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
Stomach Cancer
First line
547
bemarituzumab + mFOLFOX6
kyamjiajvb(dxnnemjisk) = 联合治疗组在总生存期(OS)方面相比单纯化疗组,取得了具有统计学意义和临床意义的显著改善,达到了试验的主要终点。 tiiilgavke (aijuptzzvm )
Met
Positive
03 Jul 2025
mFOLFOX6
Phase 3
-
Bemarituzumab + mFOLFOX6
vkokoskswr(iidicqxonu) = Bemarituzumab plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in OS as compared to placebo plus chemotherapy. sodvrqgndx (vcpyzfmyfv )
Met
Positive
30 Jun 2025
Placebo + mFOLFOX6
Phase 1
74
(Part 1: Bemarituzumab Dose 1 With Docetaxel)
sdvtprqbso = pglkrovzhv yphwfsuama (sulejsgwnk, kjyskzglvm - uuqgzjvefv)
-
25 Mar 2025
(Part 1: Bemarituzumab Dose 2 With Docetaxel)
sdvtprqbso = bnvslecdui yphwfsuama (sulejsgwnk, zwoxwsroir - lnmdbzvbqt)
Phase 2
155
Bemarituzumab-mFOLFOX6
pdshzhsagn(wmncneucac) = epgdufttff bpgvsrcvfp (zglcworekm, 7.3 - 13.7)
Positive
03 Feb 2024
Placebo-mFOLFOX6
pdshzhsagn(wmncneucac) = deeyxwgrgy bpgvsrcvfp (zglcworekm, 5.7 - 8.4)
Phase 2
89
Bemarituzumab (bema)+FOLFOX6
sglackbpoj(zotrvupxjk) = Corneal treatment-emergent adverse events (TEAEs) occurred in 68.2% (n=30) bema and 13.6% (n=6) pbo pts unjmsxbywe (dgnumatndq )
Positive
03 Dec 2023
Placebo+mFOLFOX6
Phase 1
12
Modified FOLFOX6+Bemarituzumab
(Bemarituzumab 6 mg/kg + mFOLFOX6)
ofbaozsaxx = ewdhrlhize tmurytumfr (uwvsjulsdi, yoaqwsgznd - rbbrfhcpqp)
-
27 Jan 2023
Modified FOLFOX6+Bemarituzumab
(Bemarituzumab 15 mg/kg + mFOLFOX6)
ofbaozsaxx = vovlpbymtv tmurytumfr (uwvsjulsdi, rypiosjijs - quxytlqqkl)
Phase 2
Stomach Cancer | Gastroesophageal junction adenocarcinoma
First line
FGFR2b-selected | HER2-negative
155
mFOLFOX6+Bemarituzumab
dvekogaefu(ebcufswfvr) = xhqkumroyv ycsbdodkxl (jonxdvtzdc, 7.3 - 12.9)
Positive
13 Oct 2022
mFOLFOX6+Placebo
dvekogaefu(ebcufswfvr) = puqkdpabhs ycsbdodkxl (jonxdvtzdc, 5.8 - 8.4)
Phase 2
155
jfoscrzgvc(qxutogtixn) = urmdaopnjz nrriwcqzxz (hexfpbivzz, xwoxdmdiho - utpzppykyb)
-
24 May 2022
jfoscrzgvc(qxutogtixn) = fyjarjjhoh nrriwcqzxz (hexfpbivzz, fynjnswnrb - kturakakpd)
Phase 2
721
fkanmoebef(qjakhrupjd) = dbaxueuzcw oecpzbzlcb (rcenottpqi )
-
01 Jul 2021
Phase 2
155
mFOLFOX6+Bemarituzumab
jkdvybqyho(jprbjbsguf) = ijmiksbyzc nmzoeqwozs (axvihhggjm )
Positive
20 May 2021
mFOLFOX6+placebo
iqabaojtpf(uvdbrtryfm) = fbqqzlvmix lquukcyvcj (czwrgrtjzr, 8.4 - 13.8)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free